Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Next Previous
Trial Profile

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms DESTINY-Breast11
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 08 Dec 2025 According to a Daiichi Sankyo Company media release, data from this study will be presented at the at the 2025 San Antonio Breast Cancer Symposium (#SABCS25) on December 10 to 12 2025.
  • 06 Nov 2025 According to an AstraZeneca media release, base on results from this trial, the sBLA for ENHERTU followed by paclitaxel, trastuzumab and pertuzumab (THP) has been accepted by China's NMPA.
  • 18 Oct 2025 According to a Daiichi Sankyo Company media release, results were presented in ESMO and will be published in the Annals of Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top